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In order to find novel plant-derived biologically active compounds against Trypanosoma cruzi, we isolated, from the organic
extract of Smallanthus sonchifolius, the sesquiterpene lactones enhydrin (1), uvedalin (2), and polymatin B (3) by bioassay-guided
fractionation technique.These compounds showed a significant trypanocidal activity against the epimastigote forms of the parasite
with IC
50
values of 0.84𝜇M(1), 1.09𝜇M(2), and 4.90𝜇M(3). After a 24 h treatmentwith 10𝜇g/mLof enhydrin or uvedalin, parasites
were not able to recover their replication rate. Compounds 1 and 2 showed IC
50
values of 33.4 𝜇M and 25.0 𝜇M against T. cruzi
trypomastigotes, while polymatin B was not active. When the three compounds were tested against the intracellular forms of T.
cruzi, they were able to inhibit the amastigote replication with IC
50
of 5.17 𝜇M, 3.34 𝜇M, and 9.02 𝜇M for 1, 2, and 3, respectively.
The cytotoxicity of the compounds was evaluated in Vero cells obtaining CC
50
values of 46.5𝜇M (1), 46.8𝜇M (2), and 147.3𝜇M
(3) and the selectivity index calculated. According to these results, enhydrin and uvedalin might have potentials as agents against
Chagas disease and could serve as lead molecules to develop new drugs.
1. Introduction
Chagas disease, also called American trypanosomiasis is an
endemic disease that remains as a major public health pro-
blem in Latin America. It is estimated that approximately
10 million people are infected and 100 million are at risk
worldwide, mainly due to populationmigrations.The disease
is caused by a kinetoplastid protozoan parasite, Trypanosoma
cruzi, which is primarily transmitted by blood-sucking
insects widely known in endemic countries as “kissing bugs.”
The acute clinical stage of the disease (inwhich 5%of children
die) is characterized by fever, generalized lymphadenopathy,
and hepatosplenomegaly. The chronic stage often involves
mainly cardiac and/or digestive disturbances being a leading
cause of infectious cardiomyopathy worldwide [1].
Current treatments are based on the nitro-derivatives
benznidazole and nifurtimox, two drugs developed more
than four decades ago. They are employed in acute and early
chronic cases. However, these drugs have an unsatisfactory
cure rate in the chronic disease, are frequently not well toler-
ated, and cause toxic side effects [2]. Hence, improved treat-
ment options are needed for all stages of T. cruzi infection.
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Medicinal plants produce a variety of chemical com-
pounds and are still a major source of innovative therapeutic
agents for various diseases, directly in their native form, or
more often after optimization by structural modifications or
by the synthesis of analogs with improved pharmacological
properties [3]. Many reports concerning the antiprotozoal
activity of natural compounds from plant origin have been
reported [4–9].
Smallanthus sonchifolius (Asteraceae), a herbaceous per-
ennial plant native to South America, is locally known as
“yacon,” “llacuma,” and “jiquima” or “poire de terre” and
“yacon strawberry” in Europe. The history of yacon goes far
back beyond the Incas.This plant originates from the Andean
region, whence it has spread to New Zealand, Japan, and
Brazil. It is grown throughout the Andes, from Colombia
to Northwestern Argentina [10, 11], and its cultivation and
consumption have expanded in recent decades to several
Asian and European countries [12]. Yacon has been identified
as a traditional food in the Andean region, and it is also used
as an offering during religious festivities [11]. Besides from
its use as food, yacon is also acknowledged as a medicinal
plant. Antidiabetic properties have been attributed to yacon
leaves, which are dried and used in the preparation of
tea [12]. Previous biological works have demonstrated anti-
inflammatory, antifungal, and antibacterial activities [13, 14].
Different chemical compounds such as phenolic and ent-
kaurenoic acids, related diterpenoid substances, acetophe-
none phytoalexins, and sesquiterpene lactones (STLs) were
identified in yacon leaves [15, 16].
We have already shown that STLs, mainly occurring in
the Asteraceae family, represent a class of compounds with
potential as trypanocidal leads [17–19]. Given the increasing
interest that yacon has raised in recent years due to its health
promoting properties, its potential as a medicinal plant, and
its content in STLs, we have selected S. sonchifolius in the
search for trypanocidal molecules against T. cruzi.
2. Materials and Methods
2.1. Plant Material. Leaves of Smallanthus sonchifolius
(Poepp. & Endl.) H. Robinson (Asteraceae), clone LIEY 97-2,
were collected in May 2010 from experimental crops located
at Centro Universitario “HorcoMolle,” Universidad Nacional
de Tucuma´n (26∘47󸀠 S, 65∘19󸀠W, 547m a.s.l.). A voucher
specimenwas deposited at theHerbarium of InstitutoMiguel
Lillo, S. M. de Tucuma´n, Argentina (LIL 607176).
2.2. Extraction of Plant Material. Approximately 350 g of
air-dried and ground leaves were extracted by soaking in
dichloromethane (6.8 L) at room temperature for 30min.
The procedure was repeated, and the filtrates combined.
Evaporation of the solvent under reduced pressure provided
9.29 g of organic extract (OE; 2.65%).
2.3. Bioassay-Guided Fractionation of OE and Isolation
of Compounds. The OE (9.0 g) was separated by column
chromatography (CC) on silica gel 60 (Merck, 0.063–
0.2mm/70–230mesh; 67 g) affording 10 fractions (F
1A–F5B).
Each fractionwas elutedwith 250mLof the following eluents:
n-hexane 100% (F
1A-F1B), n-hexane : ethyl acetate 1 : 1 (F2A-
F
2B.), ethyl acetate 100% (F3A-F3B), ethyl acetate :methanol
1 : 1 (F
4A-F4B), and methanol 100% (F5A-F5B). Eluates were
monitored by thin-layer chromatography (TLC) using silica
gel 60 F
254
(Merck) using hexane : ethyl acetate 1 : 1 as mobile
phase. Visualization of compounds was done by a solution of
anisaldehyde/sulfuric acid followed by heating.
Fractions F
2B and F3A were separately chromatographed
over silica gel CC (10 g) and eluted isocratically with n-
hexane : ethyl acetate (1 : 1) as mobile phase yielding 20
subfractions of F
2B (F2B1–F2B20) and 22 subfractions from F3A
(F
3A1–F3A22), of 10mL each. According to their TLC profile,
fractions F
2B5–F2B7; F2B8–F2B12; F3A6–F3A8 and F3A9–F3A13
were pooled and subjected to preparative TLC on silica gel
60 employing n-hexane : ethyl acetate 1 : 1 as mobile phase to
afford compounds 1, 2, and 3.
These compounds were recrystallized from ethanol at
96∘C and identified by spectroscopic techniques: 1H- and
13C-nuclear magnetic resonance (NMR), gas chromatogra-
phy coupled to mass spectrometry (GC/MS), and infrared
spectroscopy (IR).
2.4. Identification of Compounds 1, 2, and 3. The structure
elucidation of the isolated compoundswas performed by pro-
ton nuclearmagnetic resonance (1HNMR) and carbonNMR
(13C NMR) (Bruker 300MHz-Karlsruhe, Germany). Com-
pounds were dissolved in deuterated chloroform (Cl
3
CD),
and tetramethylsilane (TMS) was used as internal standard
(Sigma). FTIR spectra were recorded on a Nicolet 380
spectrometer using KBr pellets. The material was dried and
placed in a desiccator at 20∘C prior to pellet preparation. Gas
chromatography/mass spectroscopy spectra were recorded
on a Agilent 5973 network mass selective detector (MS),
Agilent 6890 Series GC system (GC).
2.5. Parasites, Cell Lines, and Media. T. cruzi epimastigotes
(RA strain) were grown in liver infusion tryptose medium
(LIT) supplemented with 10% fetal bovine serum (Natocor).
Cultures were routinely maintained by weekly passages at
28∘C. T. cruzi trypomastigotes were routinely maintained
by infecting 21-day-old male CF1 mice. T. cruzi amastigotes
were obtained by infecting J774 cells with bloodstream trypo-
mastigotes.
2.6. In Vitro Trypanocidal Activity against T. cruzi Epimastig-
otes and Trypomastigotes. S. sonchifolius OE and fractions
F
1A–F5B were tested for trypanocidal activity against T.
cruzi epimastigotes, at final concentrations of 10𝜇g/mL and
100 𝜇g/mL, by a [3H] thymidine uptake assay as previously
described [17]. Compounds 1, 2, and 3 were tested at final
concentrations ranging from 0.01𝜇g/mL to 50𝜇g/mL. Stock
solutions of the samples were prepared in ethanol : water
(1 : 1). Epimastigotes in exponential growth phase were
adjusted to 1.5 × 106 parasites/mL and seeded on 96-well
plates in the presence of the different concentrations of OE,
fractions, or compounds. Parasites were cultured in tripli-
cate for 72 h. Control parasites were cultured in absence
or presence of benznidazole (20𝜇M; Roche-Rio de Janeiro,
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Brazil). Percentage inhibition was calculated as 100− {[(cpm
of treated parasites)/(cpm of untreated parasites)] × 100}.
The compound concentration at which the parasite growth
was inhibited by 50% (inhibitory concentration 50, IC
50
) was
determined after 72 h.
To determine whether the parasites could recover after
treatment with the pure compounds, T. cruzi epimastigotes
were incubatedwith compounds 1–3 (0.1, 1, and 10𝜇g/mL) for
24 h. Parasites were then centrifuged at 3000 rpm for 10min,
resuspended in freshmedium, and incubated for 2 additional
days, counting the number of parasite in aNeubauer chamber
on a daily basis.
The trypanocidal effect of compounds 1, 2, and 3 was
also tested on bloodstream trypomastigotes as previously
described [17]. Briefly, mouse blood containing trypomastig-
otes was adjusted to a concentration of 1.5 × 106 parasite/mL
and seeded (150 𝜇L/well) by duplicate into a 96-well micro-
plate, in the presence of each compound (1 to 50𝜇g/mL,
final concentration). Plates were incubated for 24 h, and the
remaining live parasites were counted in a haemocytometer.
2.7. InVitro Trypanocidal Activity against T. cruzi Amastigotes.
To evaluate the effect of compounds 1–3 on intracellular
forms of T. cruzi, 96-well plates were seeded with J774
murine macrophages at 5 × 103 per well in 100 𝜇L of
culture medium and incubated for 2 h at 37∘C in a 5%
CO
2
atmosphere. Cells were infected with transfected blood
trypomastigotes expressing 𝛽-galactosidase at a parasite : cell
ratio of 10 : 1. After 2 h of coculture, plates were washed twice
with PBS to remove free parasites and compounds 1–3 were
added at 0.1–50𝜇g/mL per well in 150 𝜇L of fresh complete
RPMI medium without phenol red (Gibco, Rockville, MD).
Controls included infected nontreated cells (100% infection
control) and uninfected cells (0% infection control). The
assay was developed 48 h later by addition of chlorophenol
red-𝛽-d-galactopyranoside (100𝜇M CPRG) and 1% Nonidet
P40. Plates were incubated for 4–6 h at 37∘C. Wells with
galactosidase activity turned the media from yellow to red,
and this reaction was quantified at 590 nm in a microplate
reader (Bio-Rad Laboratories, Hercules, CA). Percentage
inhibition was calculated as 100− {[(absorbance of treated




2.8. Cytotoxicity Assay. The cytotoxic effect of compounds
1, 2, and 3 on Vero cells was evaluated by using the
MTT tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma) colorimetric assay.
Cells (5 × 104 cells/well) were seeded at a final volume of
150𝜇L in a flat-bottom 96-well microplate and cultured at
37∘C in a 5% CO
2
atmosphere in the absence or presence of
increasing concentrations of the compounds (1–50𝜇g/mL).
After 24 h, MTT was added at a final concentration of
1.5mg/mL and plates were incubated for 2 h at 37∘C. The
purple formazan crystals were completely dissolved by
adding 150 𝜇L of ethanol, and the absorbance was detected at
570 nm in a microplate reader. Results were calculated as the
ratio between optical density in the presence and absence
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Figure 1: Growth inhibition of T. cruzi epimastigotes by S. sonchi-
folius OE and fractions F
1A to F5B. Epimastigotes were cultured in
triplicate in the presence of 10 or 100 𝜇g/mL of OE or each fraction.
Cultures were done in 96-well plates with 1.5 × 106 parasites/mL
during 72 h with the addition of [3H] thymidine for the last 16 h.
Bars represent means ± SEM.
concentration (CC
50
) was calculated for each compound. All
experiments were made in duplicate.
The selectivity index (SI) of each compound was calcu-
lated as the CC
50
obtained with Vero cells divided by the IC
50
obtained against T. cruzi amastigotes.
2.9. Statistical Analysis. All values were presented as mean ±
SEM The GraphPad Prism 3.0 software (GraphPad Software
Inc., San Diego, CA) was employed to carry out calculations.
To calculate the IC
50
values, the percentages of inhibition
were plotted against the drug concentration and fitted with
a straight line determined by a linear regression (Sigma Plot
10 software). Results presented are representative of three to
four independent experiments.
3. Results
3.1. In Vitro Trypanocidal Activity of S. sonchifolius OE. The
trypanocidal activity of the organic extract of S. sonchifolius
(OE) was evaluated in vitro against T. cruzi epimastigotes by
a [3H] thymidine uptake assay. The extract was found to be
active showing a growth inhibition of 87.6%±5.3 and 95.1%±
0.5 at 100 and 10 𝜇g/mL, respectively.
The fractionation of the OE by CC yielded 10 fractions
(F
1A–F5B), the effects of which were tested against epimastig-
ote forms of T. cruzi as described previously (Figure 1).
The results showed that at the lowest concentration tested
(10 𝜇g/mL) fractions F
2B, F3A, and F3B showed the highest
trypanocidal activity with percentages of growth inhibition
of 92.7 ± 1.7%, 83.8 ± 1.1%, and 82.7 ± 1.0%, respectively.
3.2. Bioassay-Guided Fractionation of S. sonchifolius OE. The
bioassay-guided fractionation of fractions F
2B and F3A led
to the isolation of compounds 1, 2, and 3 that were purified
by a combination of column chromatography, preparative
TLC, and precipitation techniques. Compound 1 (35mg;
0.39%), compound 2 (6.4mg; 0.07%), and compound 3
(2.4mg; 0.03%) were identified by comparing their spectral
data with published values [20–22] as the STLs enhydrin































Figure 2: Chemical structures of the sesquiterpene lactones enhydrin, uvedalin, and polymatin B.

















Figure 3: Inhibition of T. cruzi epimastigotes growth by enhydrin,
uvedalin, and polymatin B. Parasites were adjusted at 1.5 × 106/mL
and incubated in triplicate in the presence of 0.01 to 50 𝜇g/mL of
each compound. Parasites were cultured for 72 h, with the addition





methyl ester), and polymatin B (8𝛽-angeloyloxi-9𝛼-acetyloxi-
1(10)E,4E,11(13)-germacratrien-12,6𝛼-olide-14-oic acidmethyl
ester) (Figure 2). Purity of the compounds (>95%) was con-
firmed by gas chromatography (GC).
3.3. In Vitro Trypanocidal Activity against T. cruzi Epimas-
tigotes and Trypomastigotes. The IC
50
values of the pure com-
pounds were calculated on different T. cruzi evolutive stages.
Figure 3 shows the effect of the pure compounds on the
growth of epimastigotes of T. cruzi. The IC
50
values for enhy-
drin, uvedalin, and polymatin B were 0.39 𝜇g/mL (0.84 𝜇M),
0.49 𝜇g/mL (1.09𝜇M), and 2.12 𝜇g/mL (4.90𝜇M), respect-
ively, after 72 h of incubation.
Moreover, after the 24 h treatment with 10 𝜇g/mL enhy-
drin or uvedalin, a drastic reduction in the amount of
parasites could be observed. Besides, two days after removal
of the compounds, no recuperation of the epimastigotes was
observed suggesting that 24 h treatment at high doses is
sufficient to kill the parasites (Figure 4). When 0.1 𝜇g/mL of
polymatin B was removed at 24 h after treatment, epimastig-
otes recovered their replication rates at values similar to the
control parasites.
The effect of the compounds against the infective form
of T. cruzi is shown in Figure 5. When bloodstream trypo-
mastigotes were incubated with the pure STLs, we observed
that enhydrin and uvedalin were active with IC
50
values of
15.5 𝜇g/mL (33.4 𝜇M) and 11.2 𝜇g/mL (25.0𝜇M), respectively.
By contrast, polymatin B showed no activity against this
parasite form.
3.4. In Vitro Trypanocidal Activity against T. cruzi Amastig-
otes. In order to evaluate the ability of the pure compounds
to inhibit the intracellular amastigote forms of T. cruzi,
J774 macrophages were infected with transfected blood try-
pomastigotes expressing 𝛽-galactosidase. Forty-eight hours
after the addition of the pure compounds, the percentage of
inhibition was determined. All the tested STLs were able to
inhibit amastigotes replicationwith IC
50
values of 2.4, 1.5, and
3.9 𝜇g/mL (5.17, 3.34, and 9.02𝜇M) for enhydrin, uvedalin,
and polymatin B, respectively (Figure 6).
3.5. Cytotoxicity Activity in Vero Cells. In vitro cytotoxicity of
the STLs on Vero cells was analyzed using the MTT assay.
Results are shown in Figure 7. When cell suspensions were
treated with enhydrin, uvedalin, and polymatin B, the CC
50
were 21.6, 21.0, and 63.7 𝜇g/mL (46.5, 46.8, and 147.3 𝜇M),
respectively.TheSIwas used to compare the toxicity formam-
malian cells and the activity against the parasites. The SI for
the intracellular form of the parasites was 9, 14, and 16.3 for
enhydrin, uvedalin, and polymatin B, respectively.
4. Discussion
In this work, the trypanocidal activity of the species Smal-
lanthus sonchifolius has been evaluated by in vitro assays.
The dichloromethane extract (OE) of this plant induced a
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Figure 4: Residual effect of enhydrin, uvedalin, and polymatin B on the growth of T. cruzi epimastigotes. Parasites were incubated in the
absence or presence of 0–10𝜇g/mLof the compounds for 24 h.The culturemediumwas replaced by a fresh one (arrow)without the compound,
and parasites were allowed to grow for 2 days. Parasites were counted in a Neubauer chamber. Symbols represent the mean ± SEM.
significant growth inhibition (95.1%) when tested against T.
cruzi epimastigotes at a concentration of 10𝜇g/mL.This result
prompted us to carry out a bioassay-guided fractionation of
the OE by chromatographic techniques. Among the tested
fractions, F
2B, F3A, and F3B presented the highest in vitro
inhibitory activity, against epimastigotes, with percentages of
growth inhibition higher than 80% at the lower concentration
tested. Further purification of F
2B and F3A, by a series of
chromatographic separations, led to the isolation of three
structurally related germacranolide STLs of the melampolide
type, which were identified as enhydrin, uvedalin, and poly-
matin B.
STLs are naturally occurring plant terpenoids with over
5000 known structures and which are mainly present in
members of the Asteraceae family [23].They exhibit a variety
of skeletal arrangements and are the largest and most diverse
category of natural products with an 𝛼-methylene-𝛾-lactone
motif [3]. STLs have been related to a broad spectrum of bio-
logical activities ranging from anticancer, antiviral, antibac-
terial, antifungal, and antiprotozoal. Many are described as
the active constituents of medicinal plants used in traditional
medicine for the treatment of inflammatory diseases [24].The
vast majority of STLs are considered quite “drug-like” mole-
cules with respect to their physicochemical properties [25].
Enhydrin, uvedalin, and polymatin B were firstly evalu-
ated for their trypanocidal activity on T. cruzi epimastigotes
showing a marked activity with IC
50
values of 0.84𝜇M,
1.09 𝜇M, and 4.90 𝜇M, respectively. These values indicated
that an increase in the trypanocidal activity was achieved
along the purification process.
Besides, epimastigotes treated for 24 h with 10𝜇g/mL of
enhydrin or uvedalin were not able to recover their initial
replication rates suggesting that the treatment at high doses
was sufficient to kill the parasites. Parasites treatedwith either
6 Evidence-Based Complementary and Alternative Medicine



















Figure 5: Effect of enhydrin, uvedalin, and polymatin B on T.
cruzi trypomastigotes. Bloodstream trypomastigotes were cultured
in duplicate in the presence of 1 to 50𝜇g/mL of the compounds.
The assay was performed employing 1.5 × 106 parasites/mL over
24 h. Remaining live parasites were counted in a Neubauer chamber.
Symbols represent the mean ± SEM.


















Figure 6: Effect of enhydrin, uvedalin, and polymatin B on T. cruzi
amastigotes. J774 phagocytic cells were infectedwith transfected try-
pomastigotes expressing 𝛽-galactosidase (10 : 1 parasite : cell ratio).
After removing free parasites, STLs were added at concentrations
ranging from 0.1 to 50 𝜇g/mL. Three days after infection, nonidet
P40 and chlorophenol red-𝛽-d-galactopyranoside (CPRG) were
added and the galactosidase activity was determined at 590 nm.
Values represent the mean ± SEM.
enhydrin or uvedalin, at 1 𝜇g/mL, or with polymatin B, at
10 𝜇g/mL, presented a reduction in the replication rate that
was close to 50% at 24 h after treatment. On the other hand,
recovery was evident when 0.1𝜇g/mL of the compounds was
employed.














Figure 7: Cytotoxicity of enhydrin, uvedalin, and polymatin B on
Vero cells. Cultures were kept for 24 h in the presence of different
concentrations (1 to 50𝜇g/mL) of the STLs. Cell viability was deter-
mined by the MTT method and was expressed as the ratio between
viable cells in the presence and absence of the compoundmultiplied
by 100. Bars represent the mean ± SEM of three experiments carried
out in duplicate.
When the isolated compounds were evaluated against
T. cruzi trypomastigotes, the results (IC
50
= 33.4 𝜇M for
enhydrin and IC
50
= 25.0𝜇M for uvedalin) showed that
this parasite stage is less sensitive than epimastigotes to the
compounds. During the initial acute phase of infection, the
nonreplicative bloodstream trypomastigotes invade different
mammalian cell types, where they transform into replicative
intracellular amastigotes and multiply within the host’s cells
cytoplasm. Interestingly, when enhydrin, uvedalin, and poly-
matin B were tested against the amastigote forms, they were
able to inhibit replication. The three STLs were active with
IC
50
values of 5.17 𝜇M, 3.34 𝜇M, and 9.02𝜇M, respectively.
The ability of compounds to inhibit the intracellular growth
of T. cruzi amastigotes is a more rigorous and relevant test
of anti-T. cruzi activity, as it is applied to a stage which is
the predominant form in mammals and because the killing
assay requires that the drug cross the host cell membrane
[26]. It is well known that the treatment with benznidazole
is especially useful for patients in the acute phase, when
trypomastigotes may be easily found in blood, while its
effectiveness during the asymptomatic or chronic stage, is still
controversial. The fact that these compounds proved to be
active against amastigotes is of particular interest, since the
DNDi organization prioritizes the development of drugs that
are useful during the indeterminate and chronic phases of the
infection, where parasites remain intracellular [1].
The therapeutic potential and the lack of cytotoxic effects
on mammalian cells are important criteria to be considered
when novel compounds with activity against T. cruzi are
investigated. Compounds containing an exomethylene moi-
ety conjugated with a carbonyl group can react as Michael-
type acceptors with the thiol groups of macromolecules such
as enzymes [3]. The presence of this reactive group in the
isolated STLs could explain the trypanocidal effects and
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the cytotoxicity of these compounds. When analyzing the
chemical structure of the STLs isolated in this work, it could
be observed that, unlike enhydrin and uvedalin, polymatin B
does not present an epoxide as substituent. Biological activity
of 𝛼-methylene-𝛾-lactones may vary according to their dif-
ferent number of alkylating structure elements such as con-
jugated cyclopentones, conjugated side-chain esters, and
epoxides [25]. These features may be related to the increased
activity shown by enhydrin and uvedalin compared to the
nonepoxide substituted polymatin B. Moreover, when com-
paring the toxicity of the lactones in Vero cells with the
activity against T. cruzi amastigotes, we could observe that
enhydrin, uvedalin, and polymatin B had some selective toxi-
city against the parasites (SI of 9, 14, and 16.3, resp.).
The three STLs had been previously isolated from S.
sonchifolius [11, 13, 15]. Enhydrin and uvedalin have shown
cytotoxic activity in cervical cancer cells [27]. For enhydrin
hypoglycemic, antibacterial, anti-inflammatory, and antihy-
peralgesic activities have also been reported [11, 28, 29], while
this is the first report of the anti T. cruzi activity of these
compounds.
5. Conclusion
Three STLs with promising antitrypanocidal properties were
isolated from the leaves of S. sonchifolius by a bioassay-
guided fractionation method. The compounds, identified as
enhydrin, uvedalin, and polymatin B, efficiently inhibited
both the epimastigote and the replicative intracellular amasti-
gotes, being more selective for the parasites than for mam-
malian cells. According to the results obtained, enhydrin
and uvedalinmay be considered promising antitrypanosomal
lead molecules. However, the potential of these compounds
still have to be improved by obtaining derivatives that might
be used as therapeutic agents against the parasite.
Further studies will involve evaluation of the underlying
mechanisms as well as in vivo studies of enhydrin and
uvedalin.
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